

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement appears for information purposes only and does not constitute an invitation or offer to sell, dispose, acquire, purchase or subscribe for any securities and neither this announcement nor anything herein forms the basis for any contract or commitment whatsoever.*

*Distribution of this announcement into jurisdictions other than Hong Kong may be restricted by law. Persons who come into possession of this announcement should acquaint themselves with and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.*

*This announcement is not for release, publication, or distribution, directly or indirectly, to any jurisdiction where such release might be unlawful. This announcement is for information purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale or purchase of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities referred to herein have not been and will not be registered under the US Securities Act of 1933, as amended (the "US Securities Act") or the laws of any state or jurisdiction of the United States, and may not be offered or sold within the United States, absent registration or an exemption from the registration requirements of the US Securities Act and applicable state laws. There is no intention to register any portion of the rights issue or any securities described herein in the United States or to conduct a public offering of securities in the United States.*



## **The United Laboratories International Holdings Limited**

**聯邦制藥國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 3933)**

**Website: <http://www.tul.com.cn>**

### **RESULTS OF THE RIGHTS ISSUE OF 325,375,000 RIGHTS SHARES AT THE SUBSCRIPTION PRICE OF HK\$2.21 EACH ON THE BASIS OF 1 RIGHTS SHARE FOR EVERY 4 EXISTING SHARES HELD ON THE RECORD DATE**

**Sole Underwriter of the Rights Issue**



#### **RESULTS OF THE RIGHTS ISSUE**

As at 4:00 p.m. on Monday, 30 April 2012, being the latest time for acceptance of and payment for the Rights Shares and for application and payment for the excess Rights Shares, 1,438 valid acceptances of provisional allotments for a total of 313,742,321 Rights Shares and 1,492 valid applications for a total of 5,907,983,493 excess Rights Shares, representing in aggregate approximately 1,912.17% of the total number of Rights Shares available for subscription under the Rights Issue, had been received.

The Underwriting Agreement and the Rights Issue became unconditional at 4:00 p.m. on Friday, 4 May 2012. As the Rights Issue was over-subscribed, the obligations of the Sole Underwriter under the Underwriting Agreement in respect of the Underwritten Shares have been fully discharged.

Based on the number of valid acceptances referred to above, the Board has resolved to allot a total of 11,632,679 Rights Shares available for excess application on a fair and equitable basis as set out below in this announcement.

It is expected that the share certificates for Rights Shares, in their fully-paid form, and the refund cheques in respect of the wholly or partially unsuccessful applications for excess Rights Shares, will be despatched by ordinary post to those entitled, at their own risk, on Wednesday, 9 May 2012.

Dealings in the Rights Shares, in their fully-paid form, are expected to commence on the Stock Exchange at 9:00 a.m. on Thursday, 10 May 2012.

Reference is made to the prospectus of The United Laboratories International Holdings Limited (the “**Company**”) dated 16 April 2012 (the “**Prospectus**”) and the announcement of the Company dated 29 March 2012 in respect of the Rights Issue. Capitalised terms used herein shall have the respective same meanings as those defined in the Prospectus unless otherwise stated.

## **RESULTS OF THE RIGHTS ISSUE**

The Board is pleased to announce that as at 4:00 p.m. on Monday, 30 April 2012, being the latest time for acceptance of and payment for the Rights Shares and for application and payment for the excess Rights Shares, 1,438 valid acceptances of provisional allotments for a total of 313,742,321 Rights Shares and 1,492 valid applications for a total of 5,907,983,493 excess Rights Shares, representing in aggregate approximately 1,912.17% of the total number of Rights Shares available for subscription under the Rights Issue, had been received.

Pursuant to the Irrevocable Undertakings, the Undertaking Shareholders have accepted or procured the acceptance of, a total of 191,125,500 Rights Shares, and have given notice to the respective borrower(s) under the stock lending agreements for the acceptance for a total of 23,750,000 Rights Shares. None of the Undertaking Shareholders applied for any excess Rights Shares under the Rights Issue.

The Underwriting Agreement and the Rights Issue became unconditional at 4:00 p.m. on Friday, 4 May 2012. As the Rights Issue was over-subscribed, the obligations of the Sole Underwriter under the Underwriting Agreement in respect of the Underwritten Shares have been fully discharged.

## **EXCESS APPLICATIONS**

Regarding the 5,907,983,493 excess Rights Shares which had been applied for by way of application under the EAFs, the Board has resolved to allot a total of 11,632,679 Rights Shares available for excess application on a fair and equitable basis based on the following principles as set out in the Prospectus:

- (1) subject to the availability of excess Rights Shares, preference has been given to applications for topping up odd-lot holdings to whole-lot holdings where it appears to the Directors that such applications are not made with the intention to abuse such mechanism; and
- (2) subject to availability of excess Rights Shares after allocation under principle (1) above, the excess Rights Shares have been allotted to Qualifying Shareholders who have applied for excess Rights Shares on a pro-rata basis with reference to their number of excess Rights Shares applied for, and with board lot allocations to be made on a best effort basis.

The allotment results in respect of the excess Rights Shares are as follows:

Number of excess Rights Shares applied for	Number of valid excess applications	Total number of excess Rights Shares applied for	Total number of excess Rights Shares allocated	Approximate percentage of allocation based on the total number of excess Rights Shares applied for in this category (Note)
500 – 1,999	1,126	2,174,168	2,174,168	100%
2,000 – 68,000,000	365	192,187,895	941,293	0.15% – 50.06%
5,713,621,430	1	5,713,621,430	8,517,218	0.15%
<b>Total</b>	<b>1,492</b>	<b>5,907,983,493</b>	<b>11,632,679</b>	

Note: Preference was given to topping-up odd lots to whole board lots.

## SHAREHOLDINGS IN THE COMPANY

To the best of the Directors' knowledge, information and belief after having made all reasonable enquiries, the shareholding structure of the Company immediately before and after completion of the Rights Issue is as follows:

	Immediately before completion of the Rights Issue		Immediately after completion of the Rights Issue	
	Number of Shares	Approximate % of the total issued Shares	Number of Shares	Approximate % of the total issued Shares
The Undertaking Shareholders (Notes 1 and 2)	764,502,000	58.74%	955,627,500	58.74%
Other Directors (Note 3)	5,142,000	0.40%	6,427,500	0.40%
Public Shareholders	531,856,000	40.86%	664,820,000	40.86%
<b>Total:</b>	<b>1,301,500,000</b>	<b>100%</b>	<b>1,626,875,000</b>	<b>100%</b>

*Notes:*

- (1) Immediately after the completion of the Rights Issue, the Undertaking Shareholders were collectively interested in 955,627,500 Shares, comprising (i) 887,500,000 Shares beneficially held by Heren, which is indirectly held by DBS Trustee H.K. (Jersey) Limited, being the trustee of the Choy Family Trust; (ii) 67,902,500 Shares beneficially held by Mr Choy; and (iii) 225,000 Shares beneficially held by Madam Ning, the spouse of Mr Choy.
- (2) The above table does not take into account redelivery of the Equivalent Securities and the Rights Shares provisionally allotted thereto. Assuming all the Equivalent Securities and the Rights Shares provisionally allotted thereto are redelivered to the Undertaking Shareholders pursuant to the respective stock lending agreements, the Undertaking Shareholders will be interested in 1,074,377,500 Shares, representing approximately 66.04% of the total issued Shares.
- (3) Does not include excess Rights Shares which may be allotted to the Directors whose Shares are deposited in CCASS as a result of their applications under the EAFs.

### **DESPATCH OF SHARE CERTIFICATES FOR RIGHTS SHARES AND COMMENCEMENT OF DEALINGS OF RIGHTS SHARES IN FULLY-PAID FORM**

It is expected that share certificates for the Rights Shares, in their fully-paid form, and the refund cheques in respect of the wholly or partially unsuccessful applications for excess Rights Shares, will be despatched by ordinary post to those entitled thereto, at their own risk, on Wednesday, 9 May 2012.

Dealings in the Rights Shares, in their fully-paid form, are expected to commence on the Stock Exchange at 9:00 a.m. on Thursday, 10 May 2012.

By order of the Board  
**THE UNITED LABORATORIES  
INTERNATIONAL HOLDINGS LIMITED**  
**Choy Kam Lok**  
*Chairman and Executive Director*

Hong Kong, 8 May 2012

*As at the date of this announcement, the Board comprises Mr Choy Kam Lok (Chairman), Ms Peng Wei, Mr Leung Wing Hon, Mr Tsoi Hoi Shan, Ms Zou Xian Hong, Ms Zhu Su Yan and Mr Fang Yuping as executive directors; Ms Choy Siu Chit as non-executive director; and Mr Chong Peng Oon, Mr Huang Bao Guang and Mr Song Ming as independent non-executive directors.*